Samsung Biologics turns 14, eyes W5tr milestone on global expansion
Founded in 2011, Samsung Biologics has rapidly ascended to become a top-tier global CDMO, with further capacity and portfolio expansion on the horizon
Samsung Biologics, the biotech arm of Samsung Group, celebrated its 14th anniversary on Monday and reaffirmed its commitment to global biopharmaceutical leadership, guided by a growth strategy built on three pillars: production capacity, portfolio diversification and global expansion.
After posting a record 4.5 trillion won ($3.2 billion) in sales last year, the company is now aiming for 5 trillion won this year — just five years after it first crossed the 1 trillion won mark in 2020.
'Over the past 14 years, Samsung Biologics has provided top-quality service to global clients and led the contract development and manufacturing organization market,' said CEO John Rim. 'We will continue to make proactive investments to enhance our competitiveness as we work together to realize our vision of enriching human life.'
Since entering the biopharmaceutical CDMO market in 2011 as a latecomer, Samsung Biologics has swiftly risen to industry leadership through aggressive capacity expansion and a rigorous focus on quality.
Its growth momentum was accelerated under the leadership of John Rim, who took the helm as CEO in late 2020. His 35 years of experience in the biopharmaceutical industry, along with an extensive global network, has helped the company break records in both orders and sales.
The production scale of the Korean biopharmaceutical company is now at an all-time high.
The company currently holds the world's largest biomanufacturing capacity at 784,000 liters, while maintaining top-tier inspection pass rates and securing more than 350 manufacturing approvals from global regulatory authorities.
With the completion of its fifth plant this month, which would add 180,000 liters of capacity, the company plans to build three additional facilities of similar scale by 2032, aiming for a total production capacity of approximately 1.32 million liters.
The company's expanded capacity is closely tied to its high volume of contract deals.
With 17 of the world's top 20 pharmaceutical companies now among its clients, the company has been bringing its presence closer to key partners through overseas offices in places such as New Jersey and Tokyo.
Since its founding, the company has secured 99 contract manufacturing agreements and 133 contract development deals, with cumulative orders totaling $16.3 billion.
Samsung Biologics surpassed 5 trillion won in total annual contract volume last year, driven in part by three major deals, each valued at over 1 trillion won. In January, the company secured its largest-ever contract manufacturing agreement worth 2.07 trillion won.
Samsung Biologics is also broadening its portfolio as part of its efforts to expand its global footprint.
In March, the company began operating a dedicated facility for antibody-drug conjugates, marking a strategic move into the market for next-generation cancer therapeutics. Future investments, the company said, will focus on new modalities, particularly in cell and gene therapies.
Beyond its commercial growth, the company remains committed to environmental, social and corporate governance initiatives within the biopharma sector.
In February, the company received the "Leadership" designation (A- rating) from the Carbon Disclosure Project in recognition of its efforts to mitigate climate-related risks.
According to the company, CEO John Rim is currently involved in the Sustainable Markets Initiative — a platform led by King Charles III to advance a sustainable future — which aims to decarbonize health care systems in collaboration with global partners.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
3 hours ago
- Korea Herald
Zyx Technology partners with AIK to promote AI-driven architectural design
Zyx Technology, a Korean digital design platform company, on Monday signed a memorandum of understanding with the Architectural Institute of Korea to bolster their partnership on AI-driven architectural design. As part of the agreement, Zyx Technology will donate 2 billion won's ($1.4 million) worth of educational licenses of its flagship computer-aided design software, ZyxCAD to AIK. The software will be distributed to students, faculty, and researchers for academic and research purposes. The partnership aims to promote domestic design technology in education, foster AI-based design automation, and support the localization of Building Information Modeling application software. Key initiatives include joint CAD training programs, technology development, regular seminars, and professional exchanges between academia and industry. ZyxCAD, registered on Korea's Public Procurement Service platform, boasts full compatibility with AutoCAD commands, shortcuts, and file formats, including LISP. Its user-friendly interface and high-speed multi-CPU processing make it suitable for both educational and industrial use. Additionally, it includes 'Works,' a CAD utility suite with over 450 features for task automation and advanced design. 'Partnering with the Architectural Institute of Korea, which sits at the intersection of academia and industry, is a meaningful opportunity to validate the technical value and practicality of ZyxCAD,' Eom Shin-jo, CEO of Zyx Technology, said. 'We look forward to working together to advance the digital design environment and expand the domestic software ecosystem.' 'This agreement comes at a pivotal time for AI in architectural design,' said AIK President Park Jin-chul. 'We'll support our members in building practical design skills with ZyxCAD.'
Korea Herald
6 hours ago
- Korea Herald
Seoul shares snap 5-day rally following US strike on Iran; won at 1-month low
South Korean stocks ended lower Monday to snap a five-day winning streak, over heightened Middle Eastern uncertainties following the United States' bombing attacks on key Iranian nuclear facilities over the weekend. The local currency was trading sharply lower against the US dollar. The benchmark Korea Composite Stock Price Index slid 7.37 points, or 0.24 percent, to close at 3,014.47, after dipping to an intraday low of 2,971.36. Trade volume was heavy at 619.8.7 million shares worth 17.76 trillion won ($12.8 billion), with losers outnumbering winners 646 to 265. Foreigners and institutions combined sold local shares worth 1.32 trillion won, while retail investors snapped up shares worth 1.4 trillion won. On Friday, the Kospi topped the 3,000-point mark for the first time in more than three years, backed by investor optimism over policies under the Lee Jae Myung administration. But investor sentiment was dampened by heightened tensions in the Middle East over the weekend. The US used B-2 bombers to launch air strikes on three key nuclear sites in Iran on Saturday, with President Donald Trump describing the operation as "successful" and claiming the Iranian sites were "obliterated." Chip and bio shares led the overall losses, with market heavyweight Samsung Electronics dropping 2.52 percent to 58,000 won and Samsung Biologics slumping 2.36 percent to 992,000 won. Battery and heavy machinery shares also retreated, with top battery manufacturer LG Energy Solution down 3.61 percent to 294,000 won and defense systems giant Hanwha Aerospace dropping 2.03 percent to 919,000 won. Automotive and shipbuilders also lost ground. Top automaker Hyundai Motor plunged 4.05 percent to 201,500 won, and leading shipyard HD Hyundai Heavy Industries slid 2.14 percent to 433,500 won. In contrast, internet-related shares and financial companies advanced. Top portal operator Naver soared 7.61 percent to 290,000 won, and KB Financial climbed 1.03 percent to 107,600 won. The local currency was trading at 1,384.3 won against the greenback at 3:30 p.m., down sharply by 18.7 won from the previous session, and marking the lowest since May 21, when the corresponding reading was 1,387.2. (Yonhap)
Korea Herald
7 hours ago
- Korea Herald
Posco to sell off non-core overseas units in China, Vietnam
Posco Group is fast-tracking the restructuring of its non-core subsidiaries, divesting low-performing overseas businesses as part of a broader strategy to reallocate resources toward high-potential sectors, particularly battery materials. According to industry sources on Monday, Posco International, the trading and resources arm of Posco Group, has agreed to sell its entire stake in Suzhou Pohang Steel to Guangdong Wcan Magnetic Materials. The transaction, valued in the 40 billion won ($29 million) range, is expected to close by June 30. Founded in 2005, Suzhou Pohang Steel, a China steel processing subsidiary, specializes in processing electrical steel and manufacturing motor components, supplying Posco products throughout eastern China. 'It is true that the sale is part of our ongoing restructuring efforts, but final confirmation from the buyer and specific deal terms are still being finalized,' a Posco Group official said. The decision reflects Posco International's strategic assessment that continued operations in China's oversaturated steel market are no longer necessary. Deteriorating conditions for Korean companies in China, exacerbated by rising geopolitical tensions such as US-China trade friction, also contributed to the move. In a separate deal, Posco Engineering & Construction is negotiating the sale of its Vietnamese subsidiary, Posco E&C Vietnam. Busan-based auto parts maker Seoil Casting has been selected as the preferred bidder, and discussions over detailed terms are underway. The subsidiary has been involved in various local construction projects, including steel structures and plant facilities. The deal is estimated to be worth around 17 billion won. Established in 1995 as a joint venture between Posco Construction and Vietnamese state-owned Lilama, holding 70 percent and 30 percent stakes respectively, Posco E&C Vietnam became wholly owned by Posco after it acquired Lilama's stake in 2010. However, the unit has faced persistent challenges, with reports indicating it had fallen into complete capital erosion by mid-2023. The recent moves are part of a broader restructuring initiative announced last year, under which Posco plans to liquidate or divest more than 120 underperforming or non-essential businesses by 2026. The goal is to raise some 2.6 trillion won to reinvest into its core pillars: steel and battery materials. As of the first quarter, the group had already achieved 40 percent of the target.
